Passage BIO (PASG) Current Deferred Revenue (2024 - 2026)
Passage BIO (PASG) posted quarterly Current Deferred Revenue of $13.8 million for Q1 2026, up 57.47% year-over-year from $8.7 million in Q1 2025, and little changed quarter-over-quarter from $13.8 million in Q4 2025.
Passage BIO (PASG) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Passage BIO's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $13.8 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 57.47% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $13.8 million (up 57.47% YoY), while the FY2025 annual figure was $13.8 million, up 67.15% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $13.8 million, roughly flat from $13.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $13.8 million in Q3 2025, with the low at $5.0 million in Q3 2024.
- The 3-year median for Current Deferred Revenue is $9.7 million (2025), against an average of $10.4 million.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue surged 175.0% in 2025, then jumped 57.47% in 2026.
- Passage BIO's Current Deferred Revenue stood at $8.2 million in 2024, then surged by 67.15% to $13.8 million in 2025, then changed by 0.0% to $13.8 million in 2026.
- Business Quant data shows PASG's Current Deferred Revenue at $13.8 million in Q1 2026, $13.8 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.25 Mn |
| Mar 31, 2026 | 13.75 Mn |
| Dec 31, 2025 | 13.75 Mn |
| Sep 30, 2025 | 13.75 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | 8.73 Mn |
| Dec 31, 2024 | 8.23 Mn |
| Sep 30, 2024 | 5.00 Mn |